Advanced Therapy Facility


The first floor of the Advanced Therapy Facility (ATF) houses an integrated cell therapy suite and clinical trials pharmacy for the manufacture of Advanced Therapy Medicinal Products (ATMP) and the dispensing of biological pharmaceuticals, gene therapy agents and vaccines.

By developing nanomedicines and targeted, personalised treatments in a dedicated and compliant facility, the CRF can offer researchers the chance to take part in the latest innovative ATMP (see below) and gene therapy trials that otherwise would not be possible.

A licensed human tissue biorepository, the Human Biomaterials Resource Centre, is on the ground floor of the ATF building.

If you would like to find out more about the ATF please contact

Dr Jane Steele
Telephone: +44 (0)121 414 7668

What are ATMPs?

An ATMP is a therapy which combine aspects of medicine, cell biology, science and engineering for the purpose of regenerating, repairing or replacing damaged tissues or cells. An ATMP is defined as either:

  1. a gene therapy medicinal product
  2. a somatic cell therapy medicinal product
  3. a tissue engineered product that contains or consists of cells or tissues that have either been subject to substantial manipulation or that are not intended to be used for the same essential function(s) in the recipient as in the donor and is presented as having properties for treating or preventing disease in human beings.